Skip to content
Research Article Open access CC BY 4.0

Research Advances Aimed at Prognosis and Treatment of Alzheimers Disease

Godwin Okoye, Rachel Vincent

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 24–29 · Published 6 Aug 2022

10.9734/jamps/2022/v24i730313

Abstract

Alzheimer's disease (AD) continues to remain a public health concern especially for seniors globally. Increased life expectancy owing to improvement in medical advances may have increased AD's prevalence. It remains a matter of concern for stakeholders to look at progress made over the years and to fill the numerous gaps targeted at preventing the onset of AD and/or treating existing condition. In recent times, funding for AD research has increased in the United States (U.S) but the economic burden isn't left out. Controversies on gene modification still exist. The search for a definitive treatment still continues since recently approved drug-Aducanumab still has uncertainty concerning safety and efficacy. Newer therapies hold promise but we are still uncertain as we await their approval and real world evidence for safety and efficacy.

Prognosis geriatrics neurology health policy genetics

References (9)

  1. 1 2021 Alzheimer's disease facts and figures [DOI]
  2. 2 Off-target Effects in CRISPR/Cas9-mediated Genome Engineering [DOI]
  3. 3 Economic burden of Alzheimer disease and managed care considerations [DOI]
  4. 4 The costs of developing treatments for Alzheimer's disease: A retrospective exploration [DOI]
  5. 5 Effects of Alzheimer Disease on Patients and Their Family [DOI]
  6. 6 Rewriting the human genome, rewriting human rights law? Human rights, human dignity, and human germline modification in the CRISPR era [DOI]
  7. 7 Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval? [DOI]
  8. 8 Medicare Coverage of Aducanumab — Implications for State Budgets [DOI]
  9. 9 Alzheimer's disease and dementia [DOI]

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

51

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.